Similar studies for GEO DataSets (Select 200160670) - GEO DataSets

Warning: The NCBI web site requires JavaScript to function. more...

Links from GEO DataSets

Items: 17

Select item 2001606701.

Adaptive responses to HER2-directed therapy in breast cancer cell line models

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing; Expression profiling by high throughput sequencing

Platform:: GPL18573
96 Samples

Download data: BW, CSV, TXT

Series

Accession:: GSE160670

ID:: 200160670

PubMed Full text in PMC Similar studies

Select item 2001617432.

Adaptive responses to targeted therapy in HER2-positive breast cancer (RNAseq) - TBCRC 036 / LCCC1214 / ClinicalTrials.gov Identifier: NCT01875666

(Submitter supplied) Inhibition of the HER2/ERBB2 receptor is a keystone to treating HER2-positive malignancies, particularly breast cancer, but a significant fraction of HER2-positive (HER2+) breast cancers recur or fail to respond. Anti-HER2 monoclonal antibodies, like trastuzumab or pertuzumab, and ATP active site inhibitors like lapatinib, commonly lack durability because of adaptive changes in the tumor leading to resistance. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL18573
34 Samples

Download data: XLSX

Series

Accession:: GSE161743

ID:: 200161743

PubMed Full text in PMC Similar studies

Select item 2001606673.

Enhancer analysis of HER2+ cell lines SKBR-3 (ER-) and BT474m1 (ER+) in response to lapatinib and JQ1 and analysis of FOXA1 chromatin binding in SKBR-3 cells in response to lapatinib and JQ1 and impact of FOXA1 knockdown on BRD4 and MED1

(Submitter supplied) SKBR-3 and BT474m1 HER2+ breast cancer cell lines were treated with lapatinib, JQ1, or lapatinib and JQ1 or (for SKBR-3) treated with siRNA pools (non-targeting control or FOXA1) prior to drug treatment before being used for ChIPseq (BRD4, MED1, H3K27Ac, or FOXA1 (for SKBR-3))

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL18573
42 Samples

Download data: BW, XLSX

Series

Accession:: GSE160667

ID:: 200160667

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 2001600184.

Adaptive responses of the HER2+ SKBR-3 and BT474m1 cell lines to lapatinib and JQ1

(Submitter supplied) SKBR-3 or BT474m1 HER2+ breast cancer cells were treated with either DMSO, 300nM lapatinib, 300nM JQ1, or lapatinib and JQ1 in combination for 48h.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL18573
8 Samples

Download data: TXT

Series

Accession:: GSE160018

ID:: 200160018

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 2001600015.

FOXA1-dependent responses of the HER2+ SKBR-3 cell line to lapatinib

(Submitter supplied) SKBR-3 HER2+ breast cancer cells were treated with 25 nM Dharmacon siGENOME non-targeting (NT) siRNA control pool or siRNA pool targeting FOXA1 for 48h, then treated with either DMSO or 300nM lapatinib for 24h.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL18573
12 Samples

Download data: CSV

Series

Accession:: GSE160001

ID:: 200160001

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 2001307886.

A Phase II Randomized Trial of Neoadjuvant Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib, Followed by Docetaxel and Carboplatin with Trastuzumab and/or Lapatinib in Patients with HER2+ Breast Cancer

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6480
199 Samples

Download data: TXT

Series

Accession:: GSE130788

ID:: 200130788

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2001307877.

(Submitter supplied) Adjuvant docetaxel, carboplatin, and trastuzumab (TCH) is a standard regimen for HER2+ breast cancer. Dual HER2-blockade with lapatinib (L) and trastuzumab demonstrated significant activity in the metastatic and neoadjuvant settings. This study evaluates neoadjuvant TC plus trastuzumab (H) and/or lapatinib (L). This study demonstrated a similar pCR rate with TCH and TCHL and a lower rate of pCR with TCL. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6480
89 Samples

Download data: TXT

Series

Accession:: GSE130787

ID:: 200130787

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2001307868.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6480
110 Samples

Download data: TXT

Series

Accession:: GSE130786

ID:: 200130786

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000184969.

Breast Cell Lines: Experimental vs. Mixed Reference

(Submitter supplied) Transcriptional profiling of breast cell lines comparing breast cell line mixed reference with individual breast cell lines. Goal was to characterize breast cell line subtypes.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL7264
51 Samples

Download data: TXT

Series

Accession:: GSE18496

ID:: 200018496

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20014638010.

RNA sequencing of trastuzumab plus pertuzumab-refractory tumor in a mouse xenograft model

(Submitter supplied) We report RNA sequencing data of trastuzumab plus pertuzumab-refractory tumor in a mouse xenograft model.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL24676
2 Samples

Download data: TXT

Series

Accession:: GSE146380

ID:: 200146380

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20014630711.

RNA sequencing of T-DM1-refractory tumor in a mouse xenograft model

(Submitter supplied) We report RNA sequencing data of T-DM1-refractory tumor in a mouse xenograft model.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL24676
2 Samples

Download data: TXT

Series

Accession:: GSE146307

ID:: 200146307

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 20013205512.

Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer [RNA-seq]

(Submitter supplied) Despite effective strategies, therapy resistance in HER2+ breast cancer remains a challenge. While the Mevalonate pathway (MVA) is suggested to promote cell growth and survival, including in HER2+ models, its potential role in resistance to HER2-targeted therapy is unknown. Using HER2+ breast cancer parental (P) cell models (AU565, SKBR3, and UACC812), we have established anti-HER2-resistant derivatives made resistant to lapatinib (LR) or lapatinib plus trastuzumab (LTR). more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL11154
15 Samples

Download data: TXT

Series

Accession:: GSE132055

ID:: 200132055

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 20006639913.

Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with chemotherapy plus trastuzumab and lapatinib as neoadjuvant therapy for HER2-positive breast cancer

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by array; Genome variation profiling by SNP array

Platforms:: GPL6801 GPL570
156 Samples

Download data: CEL, CNCHP

Series

Accession:: GSE66399

ID:: 200066399

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20006639814.

(Submitter supplied) The CHER-LOB randomized phase II study showed that the combination of lapatinib and trastuzumab plus chemotherapy increases the pathologic complete remission (pCR) rate as compared to chemotherapy plus either trastuzumab or lapatinib. An extensive biomarker programme was prospectively planned to identify potential predictors of sensitivity to different treatments and evaluate treatment effect on tumor biomarkers. more...

Organism:: Homo sapiens

Type:: Genome variation profiling by SNP array

Platform:: GPL6801
68 Samples

Download data: CEL, CNCHP, TXT

Series

Accession:: GSE66398

ID:: 200066398

PubMed Full text in PMC Similar studies

Select item 20006630515.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL570
88 Samples

Download data: CEL

Series

Accession:: GSE66305

ID:: 200066305

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20002228816.

Controlled ErbB receptor dimerization

(Submitter supplied) In order to better understand signaling events following receptor dimerization involving HER2, we have generated an experimental system in which ErbB dimerization can be controlled. We used gene expression microarrays to identify genes and pathways that are differentially activated by HER2 homodimers and HER2 containing heterodimers.

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS4361
Platform:: GPL6244
12 Samples

Download data: CEL, CHP

Series

Accession:: GSE22288

ID:: 200022288

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 436117.

AP1510, TGFα or heregulin ligand effect on MCF10 mammary epithelial cells expressing HER2-FKBP-HA chimeric receptors

Analysis of mammary epithelial MCF10A/HER2/FKBP/HA cells treated with AP1510 to induce the chimeric HER2-FKBP molecule to homodimerize, or with TGFα or heregulin to induce heterodimerization with EGFR or HER3. Results provide insight into signaling events following HER2 receptor dimerization.